Biotinylated SARS-CoV-2 Spike RBD (Wild type)

Product Description

Biotinylated SARS-CoV-2 Spike RBD (Wild type)
Catalog number: B2010506
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 ug
Molecular Weight or Concentration: 27 kDa
Supplied as: Liquid Solution
Applications: molecular component of many serological and antigenic assays for SARS-CoV-2
Storage: -20℃
Keywords: Spike RBD, S1 RBD, Wild Type RBD, Biotin RBD
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the
pandemic coronavirus: Molecular and structural insights. J Basic Microbiol. 2021
Mar;61(3):180-202.

2: Liu Z, Xu W, Xia S, Gu C, Wang X, Wang Q, Zhou J, Wu Y, Cai X, Qu D, Ying T,
Xie Y, Lu L, Yuan Z, Jiang S. RBD-Fc-based COVID-19 vaccine candidate induces
highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target
Ther. 2020 Nov 27;5(1):282.

3: Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, Zhang X, Deng J, Chen T, Song Z,
Qiao Y, Zhan Y, Liu J, Zhang J, Zhang X, Peng Z, Li Y, Lin Y, Liang L, Wang G,
Chen Y, Chen Q, Pan T, He X, Zhang H. Nanoparticle Vaccines Based on the
Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust
Protective Immune Responses. Immunity. 2020 Dec 15;53(6):1315-1330.e9.

4: Huang WC, Zhou S, He X, Chiem K, Mabrouk MT, Nissly RH, Bird IM, Strauss M,
Sambhara S, Ortega J, Wohlfert EA, Martinez-Sobrido L, Kuchipudi SV, Davidson
BA, Lovell JF. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by
Particulate Vaccination. Adv Mater. 2020 Dec;32(50):e2005637.

5: Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S,
Costa C, Nunes-Cabaço H, Mendes AM, Gaspar P, Pereira-Santos MC, Rodrigues F,
Condeço J, Escoval MA, Santos M, Ramirez M, Melo-Cristino J, Simas JP,
Vasconcelos E, Afonso Â, Veldhoen M. Seroprevalence of anti-SARS-CoV-2
antibodies in COVID-19 patients and healthy volunteers up to 6 months post
disease onset. Eur J Immunol. 2020 Dec;50(12):2025-2040.

6: Luan J, Jin X, Lu Y, Zhang L. SARS-CoV-2 spike protein favors ACE2 from
Bovidae and Cricetidae. J Med Virol. 2020 Sep;92(9):1649-1656.

7: Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, Wang P, Liu D, Yang J, Holmes EC,
Hughes AC, Bi Y, Shi W. A Novel Bat Coronavirus Closely Related to SARS-CoV-2
Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein.
Curr Biol. 2020 Jun 8;30(11):2196-2203.e3.

8: Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, Wang Z, Wu L, Zhu M, Li J, Wang Z,
Wu W, Li W, Bosco B, Gan Z, Qiao Q, Wu J, Wang Q, Wang S, Xia X. Dynamic changes
in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from
COVID-19. Nat Commun. 2020 Nov 27;11(1):6044.

9: Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and
potential therapeutics of COVID-19: A comprehensive review. J Med Virol. 2021
Jan;93(1):275-299.
10: Diao B, Wen K, Zhang J, Chen J, Han C, Chen Y, Wang S, Deng G, Zhou H, Wu Y.
Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-
CoV-2 infection. Clin Microbiol Infect. 2021 Feb;27(2):289.e1-289.e4.

Products Related to Biotinylated SARS-CoV-2 Spike RBD (Wild type): SARS-CoV-2